

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



WUXI APPTEC CO., LTD.*
無錫藥明康德新藥開發股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock Code: 2359)

ANNOUNCEMENT ON PRELIMINARY FINANCIAL DATA
FOR THE SIX MONTHS ENDED JUNE 30, 2020

This announcement is made by WuXi AppTec Co., Ltd.* (無錫藥明康德新藥開發股份有限公司) (the “**Company**”, and together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09(2)(a) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The Company is pleased to announce the key financial results for the six months ended June 30, 2020 (the “**Reporting Period**”) with comparison against those for the six months ended June 30, 2019 (the “**Corresponding Period**”). The financial results set out in this announcement are preliminary and prepared under the China Accounting Standards for Business Enterprises (or International Financial Reporting Standards (“**IFRS**”) if stated specifically), which has not been audited or reviewed by an accounting firm. The specific financial data and operating results of the Group for the Reporting Period to be disclosed in the interim results announcement of the Group for the Reporting Period (the “**2020 Interim Results Announcement**”) should prevail.

Investors should pay attention to the investment risks involved.

I. MAJOR CONSOLIDATED FINANCIAL DATA AND INDICATORS FOR THE REPORTING PERIOD

Unit: RMB In Thousand

Item	The three months ended June 30, 2020	The three months ended June 30, 2019	Increase (%)	The six months ended June 30, 2020	The six months ended June 30, 2019	Increase (%)
Total operating revenue	4,043,919	3,124,893	29.41	7,231,434	5,894,358	22.68
Operating profit	1,511,024	779,249	93.91	1,931,271	1,287,074	50.05
Total profit	1,506,129	776,596	93.94	1,921,962	1,281,467	49.98
Net profit attributable to the owners of the Company	1,414,114	668,730	111.46	1,717,155	1,056,762	62.49
Adjusted non-IFRS net profit attributable to the owners of the Company	942,414	658,644	43.08	1,518,741	1,178,676	28.85
Basic earnings per share (RMB)	0.61	0.29	110.34	0.75	0.46	63.04
Weighted average return on net assets (%)	7.67	3.67	Increased by 4.00 percentage points	9.40	5.80	Increased by 3.60 percentage points
				As at the end of the Reporting Period	As at the beginning of the Reporting Period	Increase (%)
Total assets		30,922,087			29,239,134	5.76
Equity attributable to the owners of the Company		18,532,474			17,312,255	7.05
Share capital		2,311,577			1,651,127	40.00
Net assets per share attributable to the owners of the Company (RMB)		8.02			7.49	7.05

Notes:

- The balances as at the beginning of the Reporting Period were the same as the audited ending balances of December 31, 2019.

2. The figures of the Reporting Period were extrapolated from the unaudited consolidated results of the Group.
3. When calculating the basic earnings per share and net assets per share attributable to the owners of the Company, the share capital as at June 30, 2019 and December 31, 2019 has been adjusted to reflect the 2018 and 2019 profit distribution plan and capitalization of reserve which have been implemented in 2019 and 2020, respectively, where 4 capitalization shares of the Company were issued for every existing 10 shares of the Company under both plans.

II. EXPLANATORY STATEMENT ON OPERATING RESULTS AND FINANCIAL CONDITIONS

During the Reporting Period, the Company gradually recovered from the COVID-19 epidemic and achieved strong growth in the second quarter. When compared to second quarter of 2019, the Company expects to record a quarter-over-quarter (“**QoQ**”) increase in total operating revenue of approximately 29.41%, a QoQ increase in the net profit attributable to owners of the Company of approximately 111.46%, and a QoQ increase in basic earnings per share of approximately 110.34%.

For the first half year of 2020, the Company expects to record a year-over-year (“**YoY**”) increase in total operating revenue of approximately 22.68%, a YoY increase in net profit attributable to owners of the Company of approximately 62.49%, and a YoY increase in basic earnings per share of approximately 63.04%.

The primary reasons for the increase of the Company’s total operating profit, total profit, net profit attributable to owners of the Company, basic earnings per share and share capital are as follows:

1. Total operating revenue

While the revenue and profits of the US-based laboratory services of the Company were negatively impacted in the second quarter of 2020 due to the effects of COVID-19 in the U.S., the China-based laboratory services and CDMO (Contract Development Manufacture Organization) services segments of the Company were fully operational and benefitted from increased demand from overseas customers. The Group achieved strong growth in its operating revenue in the second quarter driven by strong demand, increase in capacity utilization and efficient operations. Concurrently, our clinical CRO (Contract Research Organization) and SMO (Site Management Organization) services are also in gradual recovery.

2. Non-recurring items

The amount of non-recurring items of the Company increased in the first half of 2020 compared to the corresponding period of the previous year, due primarily to the fair value gain of the Company's investment portfolio of approximately RMB1,031.16 million largely driven by certain portfolio companies' market value appreciation, compared to a fair value loss of RMB18.25 million in the corresponding period of the previous year. Among which, the Company changed its accounting treatment for investments in a portfolio company resulting in a recognition of RMB351.49 million investment income in the Reporting Period. This was partially offset by the fair value loss of RMB486.80 million resulting from appreciation of the conversion right non-cash value of the convertible bonds issued by the Company in 2019.

3. Implementation of the 2019 profit distribution plan

Pursuant to the approval received at the 2019 annual general meeting, the first A share class meeting for 2020 and the first H share class meeting for 2020 of the Company, the 2019 profit distribution plan was implemented in the second quarter of 2020. As at the record date for the implementation of the 2019 profit distribution plan, total share capital on record for the Company was 1,651,126,531 shares, pursuant to which a cash dividend of RMB0.3370 (inclusive of tax) per share was distributed to all shareholders, along with the issuance of 4 capitalization shares of the Company for every existing 10 shares of the Company. The total cash dividend distributed was RMB556,429,640.95 (inclusive of tax) and 660,450,612 shares were issued. As a result, the Company's share capital increased by 40% as at the end of the Reporting Period compared to the beginning of the Reporting Period.

III. RISK WARNINGS

The key financial results of the Group for the Reporting Period as presented in this announcement are preliminary, and there may be differences from the final financial results to be disclosed in the 2020 Interim Results Announcement and the 2020 Interim Report of the Group after our auditor's review. However, it is not expected that any difference between the preliminary results and the final results will be more than 10%. Investors are thereby advised to exercise prudence when considering any investment decision.

Shareholders and potential investors should exercise caution when dealing in the securities of the Company and read carefully the 2020 Interim Results Announcement, which is expected to be published in August 2020.

By order of the Board
WuXi AppTec Co., Ltd.*
Dr. Ge Li
Chairman

Hong Kong, July 20, 2020

As at the date of this announcement, the Board comprises Dr. Ge Li, Mr. Edward Hu, Dr. Steve Qing Yang, Mr. Zhaohui Zhang and Dr. Ning Zhao as executive Directors, Mr. Xiaomeng Tong and Dr. Yibing Wu as non-executive Directors and Dr. Jiangnan Cai, Ms. Yan Liu, Mr. Dai Feng, Dr. Hetong Lou and Mr. Xiaotong Zhang as independent non-executive Directors.

* *For identification purpose only*